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Pharmacotherapeutic management of patients with heart
failure has become extraordinarily complicated and requires
several drugs in most patients (1). This is because our
understanding of the pathophysiology of the syndrome has
increased over the last two decades, and treatment schemes
have evolved in direct response to observations made clini-
cally and experimentally. Clinical trials completed over this
period have defined better practices, and simply treating
heart failure patients with digoxin and diuretic agents is now
passe. Angiotensin-converting enzyme (ACE) inhibitors
and beta-adrenergic blockers, often combined with digoxin
and diuretic agents, have emerged as quintessential agents to
decrease heat failure’s troubling morbidity and mortality.
Nonetheless, the reasons why these important treatment
schemes work are not completely understood, and conten-
tion arises when proper dosing strategies are debated.
Initially heart failure treatments and drug dosages were
chosen based on favorable hemodynamic responses to vaso-
dilators, in particular, those acutely produced in the coro-
nary care unit or cardiac catheterization laboratory (2). In
the late 1960s and early 1970s, there was some suggestion
that drugs with vasodilating capabilities would result in
better exercise tolerance and diminished symptoms (3). In
1980, the seminal Veterans Administration Cooperative
Vasodilator in Heart Failure Study (now commonly referred
to as V-HeFT-I) was initiated to test the concept that
peripheral vasoconstriction contributed to progressive dete-
rioration of left ventricular function and premature death in
heart failure and that vasodilators would interdict this
deleterious process (4). The results are well known and
suggested that the combination of an aggressive dosing
protocol of hydralazine (300 mg/day) combined with isosor-
bide dinitrate (160 mg/day), when added to digoxin and
diuretic agents in patients with chronic congestive heart
failure, had a favorable effect on left ventricular function and
mortality. Sometimes overlooked is the fact that prazosin,
an efficacious vasodilating and antihypertensive agent also
studied in this project, fared no better than placebo with
respect to outcomes. Indeed, not all vasodilating agents have
done well in heart failure patients (note outcomes with
respect to calcium channel blockers and prostacyclin, in
particular) (1). Vasodilation, though likely important, seems
not to be the major reason why patients with heart failure
improved with some agents (despite the fact that many of
these compounds have primarily been classified as such).
The Cooperative North Scandinavian Enalapril Survival
Study (CONSENSUS) published one year after V-HeFT-I
in 1987, demonstrated that enalapril, then generally thought
of as a vasodilating agent but known to have other putative
beneficial properties, precipitated a dramatic mortality re-
duction when added to diuretic agents and digoxin in
severely ill congestive heart failure patients (5). Subse-
quently the head-to-head comparison of enalapril with the
hydralazine–isosorbide dinitrate combination showed the
vasodilator with additional neurohumoral blocking and
cyclooxygenase pathway effects (the ACE inhibitor) to be
winner in the second V-HeFT trial (V-HeFT-II) (6).
Studies of Left Ventricular Dysfunction (SOLVD) con-
firmed the importance of the ACE inhibitor, enalapril, in
heart failure (7,8) and pointed out the importance of such an
agent even when symptoms were minimal or entirely absent
(8). These, as well as other now classic and often quoted
clinical heart failure trials, established the overriding impor-
tance of ACE inhibitors in heart failure, but led Dr. J. N.
Cohn to comment in 1996 (one decade after the publication
of V-HeFT-I) that it was “. . . uncertain whether the
remarkable response to these drugs [ACE inhibitors] in
patients with cardiovascular disease can be attributed to
hemodynamic effects, to the reduction in the level of
angiotensin II in the plasma or tissue, to increased plasma
concentrations of bradykinin or nitric oxide, or to inhibition
of the sympathetic nervous system.” (9). The debate about
why ACE inhibitors are so effective in heart failure is
highlighted by current efforts to employ angiotensin recep-
tor blocking (ARB) agents to achieve the same benefits as
ACE inhibitors, but without some of the ACE inhibitors’
specific problems, which limit their use in ;20% of the
target population (10). Absence of the ARB agents’ ability
to increase bradykinin likely makes these drugs easier to use
and better tolerated, but may account for less pharmacologic
benefit in some settings. As the Randomized Evaluation of
Strategies for Left Ventricular Dysfunction (RESOLVD)
trial design suggests, many investigators believe that ACE
inhibitors combined with ARBs will benefit heart failure
patients more than when either agent is used alone. How-
ever, might ACE inhibitor benefit in heart failure patients
accrue through pharmacologic actions not previously char-
acterized?
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In this issue of JACC, Gullestad et al. (11) report data that
strengthens already robust clinical trial information support-
ing the use of ACE inhibitors in heart failure, and thus
documenting the fact that large doses of these compounds
are necessary to most effectively ameliorate a perturbed
humoral milieu, particularly the cytokine environment. Im-
portantly, this study suggests that high doses of enalapril
(40 mg daily) in patients with severe congestive heart failure
significantly decreased interleukin (IL)-6 activity, which is
believed to be important during detrimental heart failure
remodeling (12–15). The decrease in IL-6 was associated
with diminished interventricular septal thickness observed
over time with echocardiography. These findings were not
apparent when lower enalapril doses (5 mg daily) were used.
Just as we have learned much in the last decade about which
drugs to prescribe for patients with heart failure, the
importance of proper dosing has also become more clear.
We now know that some drugs are best prescribed at a fixed
dose, whereas others should be force-titrated to target levels.
Still, it was disappointing to see that not all seemingly evil
inflammatory humors were interdicted by enalapril even at
high doses, and it is likely that more direct immunomodu-
lating treatments will be necessary to further improve the
heart failure milieu when symptoms are severe. Also, it is
not clear how ACE inhibitors produced the cytokine
response noted. It is still uncertain whether there is a direct
link between the reduction of IL-6 and inhibition of ACE.
Still, this report supports the notion that higher rather than
lower doses of ACE inhibitor are superior, and it is
particularly intriguing because of the nagging question of
just how ACE inhibitors work in heart failure.
Much information now suggests that cytokines, particu-
larly tumor necrosis factor (TNF)-alpha and IL-6, play
significant roles in various inflammatory conditions (16). It
is not surprising, therefore, to see evidence supporting the
contention that inflammatory cytokines are upregulated in
patients with advanced heart failure (likely in an attempt to
heal the injured myocardium given the fact that inflamma-
tion is the crux of our body’s repair mechanism). Almost a
decade ago, Levine et al. (17) demonstrated that circulating
levels of TNF-alpha are elevated in patients with severe
chronic heart failure, and subsequent studies noted that
TNF-alpha increased in a variety of cardiac injury states
including myocarditis (18) and acute coronary syndromes
(19,20). All of these conditions have been shown to benefit
from ACE inhibitors prescribed long term, and it is
tantalizing to suggest, as have Gullestad et al. (11), that
ACE inhibitor benefit relates to downregulation of cytokine
activity, at least in part.
Of additional interest is the report from Gurantz et al.
(21), that upregulation of the angiotensin type 1 receptor
(AT1) on cardiac fibroblasts, which is important with
respect to remodeling regulation, occurred after TNF-alpha
exposure. Using quantitative competitive reverse transcrip-
tion–polymerase chain reaction, these investigators found
that norepinephrine, endothelin, atrial natriuretic peptide
and bradykinin had no significant effect on AT1 messenger
ribonucleic acid (mRNA) levels. In contrast, TNF-alpha
produced a fivefold increase in AT1 mRNA, whereas angio-
tensin II, transforming growth factor-beta and basic fibro-
blast growth factor significantly reduced AT1 mRNA levels.
These observations further link cytokine TNF-alpha to
detrimental cardiac remodeling in heart failure.
Indeed, cytokines, and TNF-alpha, in particular, are an
emerging therapeutic target in patients with heart failure.
Important observations with respect to this issue include the
fact that drugs that increase intracellular cyclic adenosine
monophosphate (cAMP), such as pentoxifylline, amrinone
and adenosine, prevent TNF-alpha mRNA accumulation
by blocking the transcriptional activation of TNF-alpha
(13). Thalidomide, in contrast, appears to diminish TNF-
alpha by increasing mRNA degradation (22), whereas
steroids (dexamethasone) appear to suppress TNF-alpha
biosynthesis at the translational and transcriptional level
(23). Whether any of these agents are effective in attenuat-
ing long-term heart failure morbidity and mortality is
speculative, at best. Nonetheless, the recent report of
Deseval et al. (24) is intriguing in that a soluble TNF-alpha
receptor that neutralizes the biologic effect of circulating
TNF-alpha improved functional status and quality of life in
patients with advanced heart failure. This small but well-
done study provides support for the concept of giving agents
that attenuate cytokine perturbation in heart failure and sets
the stage for a large randomized clinical trial of eternacept
(14). It would be most interesting if ACE inhibitors, drugs
already proven effective in heart failure, could be added to
the list of agents that beneficially modulate cytokine pro-
duction.
Several notes of caution must be raised about the Gulle-
stad et al. study (11), some of which the authors themselves
address. All patients were receiving low dose ACE inhibitor
therapy at baseline blood sampling, and the effects of ACE
inhibition de novo on these patients’ cytokine levels are
unknown. Furthermore, no placebo group was included,
and we therefore cannot determine whether the changes, or
lack thereof, in cytokine activity simply represent the natural
variability of circulating levels of cytokines in heart failure.
Indeed, Dibbs et al. (25) have recently examined variability
in cytokine levels in patients with heart failure as compared
with normal control subjects. Circulating levels of TNF-
alpha, soluble TNF receptors 1 and 2, IL-6 and IL-6
receptor were measured daily, weekly and monthly in 10
patients with New York Heart Association (NYHA) func-
tional class III congestive heart failure and 10 healthy
volunteers. The coefficient of variation for TNF-alpha and
IL-6 levels increased with time in patients, with the
coefficient of variation in heart failure patients greatest for
IL-6. The coefficient of variation in cytokine receptor levels
was minimal and did not differ significantly between heart
failure patients and control subjects. This study suggests
that the sample size needed to show a statistically as well as
biologically significant change in the circulating level of a
2069JACC Vol. 34, No. 7, 1999 Young
December 1999:2068–71 Editorial Comment
given cytokine will vary depending on the specific cytokine
studied and period of observation. The authors stated, for
example, that to detect a 15% reduction of either circulating
TNF-alpha or IL-6 levels during a 16-week period, at an alpha
level of 0.05 and with a power of 80%, a sample size of 21
(for TNF-alpha) and 377 (for IL-6) would be required.
Gullestad et al. (11) followed 75 patients with variables
assessed at 10 and 32 weeks as compared with baseline.
If the observations made by Gullestad et al. (11) are
confirmed, the implication that ACE inhibitors are pleio-
tropic in their beneficial effects in heart failure should come
as no surprise, because heart failure is such a plastic clinical
entity and ACE inhibitors have produced remarkably con-
sistent benefits from trial to trial and in a wide range of
patients and conditions. However, the issue of high doses
versus low doses of ACE inhibitors must again be ad-
dressed. In contradistinction to diuretic agents, ACE inhib-
itors have not been, in large-scale clinical trials, titrated
according to an individual’s symptoms. Rather, target doses
were picked and forced titration schemes developed (26).
Target doses of these agents have generally been equated to
150 to 300 mg/day of captopril or 20 to 40 mg/day of
enalapril. Unfortunately, when clinical practice patterns are
analyzed, ACE inhibitors, when used, are prescribed at
much lower doses (25 to 50 mg/day of captopril and 2.5 to
5.0 mg/day of enalapril) (27,28). However, as the Gullestad
et al. study (11) and others demonstrate, higher doses of
ACE inhibitors produce greater hemodynamic, neurohor-
monal, inflammatory cytokine, symptomatic and prognostic
benefits than do lower doses. For example, Pacher et al. (29)
demonstrated that high dose enalapril treatment proved
superior to low dose treatment with respect to symptom-
atology, despite similar effects on hemodynamic variables
and maximal exercise capacity. Levine et al. (30) demon-
strated that up-titration of ACE inhibitors to high doses
(when accompanied by nitrate therapy) was well tolerated
and improved clinical status and left ventricular systolic
function. This group subsequently demonstrated that up-
titration of lisinopril to a mean dose of 55 mg/day (and
isosorbide dinitrate dose up to a mean of 286 mg/day)
resulted in significant reversal of left ventricular remodeling
(31). Van Veldhuisen et al. (32) evaluated the long-acting
ACE inhibitor, imidapril, in 244 patients randomized to
receive 2.5, 5 or 10 mg/day. At three-month follow-up, higher
doses were superior with respect to a more pronounced
effect on exercise capacity and some neurohomones, but this
did not seem to be related to the extent of suppression of
plasma levels of converting enzyme. Importantly, these
higher doses were reasonably well tolerated.
Perhaps the most convincing evidence about higher doses
of ACE inhibitors comes from the Assessment of Treat-
ment with Lisinopril And Survival (ATLAS) clinical trial
(28,33,34). The ATLAS trial was designed to determine
whether high doses of lisinopril would result in lower
mortality and morbidity than lower doses in comprable
patients. It was a large, randomized, double-blinded, mul-
ticenter, international trial (287 clinical centers in 19 coun-
tries) in patients with an ejection fraction #30% (NYHA
functional class II, III or IV). Low dose lisinopril was
defined as 2.5 to 5 mg/day and high dose 30 to 40 mg/day.
The primary outcome evaluated was all-cause mortality,
with secondary end points including cardiovascular mortal-
ity and morbidity. Patients were followed for an average of
3.5 years and over 3,000 individuals were randomized. By
the end of the study, almost 45% of patients in the low dose
group had died as compared with 43% in the high dose
group, but this difference was not statistically significant
(p 5 0.128). In contrast, hospital admissions for congestive
heart failure were reduced by 24% in the high dose lisinopril
group (p 5 0.003). In addition, the combined end point of
all-cause mortality and cardiovascular morbidity was lower
in the high dose group (84% vs. 80%, p 5 0.002).
Another complementary but smaller study was done by
Luzier et al. (35). This effort evaluated the relation of
digoxin, diuretic agents and ACE inhibitors (and dose) to
hospital readmission rates over a 36-month period. The
ACE inhibitor dose response analysis used the discharge
dose and converted this to enalapril equivalent doses, while
adjusting for renal dysfunction. Interestingly, only 22% of
those patients taking ACE inhibitors in this study of 314
patients received currently recommended doses of enalapril
(20 mg/day or its equivalent) and 41% received ,5 mg of
enalapril (or its equivalent) per day. Time for readmission
was increased when an ACE inhibitor was used overall in
the study (p 5 0.002), and these agents were the principal
covariate of 90-day decreased readmission rates. However,
readmission rates were not reduced when the daily dose was
#5 mg of enalapril equivalents per day. When patients
received daily doses .10 mg equivalents, the 90-day read-
mission rate was decreased by almost 30%, as compared
with those receiving a diuretic agent or digoxin alone (p ,
0.05). Similarly, Gattis et al. (36) explored ACE inhibitor
doses in elderly patients with heart failure and noted them
to be less than optimal, with low doses associated with more
clinical events. None of these studies give insight into the
mechanism of ACE inhibitors’ differential effects based on
dose, but they all are in concert with the findings of
Gullestad et al. (11). From a pathophysiologic viewpoint,
higher doses of ACE inhibitors make sense, and we have
learned that much of the beneficial effects of these drugs
may be unrelated to de facto hemodynamic changes. We
must strive harder to clarify the nuances of ACE inhibitors’
actions in heart failure. One cannot help but wonder
whether ACE inhibitor cytokine modulating effects, if,
indeed, they are present, would help with the headache
associated with this challenge!
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